ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0456

Reduced Risk of Serious Pneumococcal Infection up to 10 Years After Immunization with 7-valent Conjugated Pneumococcal Vaccine in Patients with Inflammatory Arthritis

Johanna Nagel1, Göran Jönsson2, Jan Åke Nilsson3, Chanchai Manuswin4, Martin Englund5, Tore Saxne1, Pierre Geborek1 and Meliha Kapetanovic1, 1Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden, Lund, Sweden, 2Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Infection Medicine, Lund, Sweden, Lund, Sweden, 3Rheumatology, Department of Clinical Sciences, Malmö, Lund University. Department of Rheumatology, Skåne University Hospital, Malmö and Lund, Sweden, Malmö, Sweden, 4Centre of Registers South, Skåne University Hospital, Lund, Sweden, Lund, Sweden, 5Lund University, Lund, Sweden

Meeting: ACR Convergence 2020

Keywords: Infection, rheumatoid arthritis, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Infection-related Rheumatic Disease (0454–0458)

Session Type: Abstract Session

Session Time: 10:00AM-10:50AM

Background/Purpose: The aim was to examine the rates of putative pneumococcal infections up to 10 years before and after administration of heptavalent conjugated pneumococcal vaccine (PCV7) in patients with inflammatory arthritis compared to non-vaccinated arthritis patients.

Methods: Adult patients with rheumatoid arthritis (RA) and spondylarthropathy (SpA) including psoriatic arthritis (PsA) patients, at the Department of Rheumatology at Skåne University Hospital, Sweden were offered one single intramuscular dose of PCV7 between May 2008 and February 2012. 595 patients participated (RA=342; 80% women, and SpA=253; 45% women). Mean age was 62 and 51 years, mean disease duration was 16 and 14 years respectively. For each patient, 4 reference subjects were identified, matched for arthritis diagnosis, age, sex, and geographical area, and date of vaccination of the patient was also used as index date for its references. References were presumed to be non-vaccinated for pneumococci, following the current national guidelines.

At the time of vaccination, 420 patients were treated with bDMARDs including anti-TNF agents (n=330), tocilizumab (n=15), abatacept (n=18), anakinra (n=1) and rituximab (n=56). Methotrexate (MTX) was given as monotherapy (n=86), or in combination with bDMARD (n=220). Eighty-nine of the SpA patients were treated with NSAIDs without DMARD. Thirty percent (n=176) of the patients were treated with prednisolone, mean weekly dose 41 (1-140) mg.

The Skåne Healthcare Register was searched for ICD-10 diagnostic codes for serious putative pneumococcal infections between January 2000 and December 2018 for both patients and reference subjects. The outcome events included community acquired pneumonia, lower respiratory tract infection, septicemia, meningitis, and septic arthritis. We compared the frequency of outcome events after vs before date of vaccination by calculating relative risks (RRs). The ratio of relative risk (RRR) was calculated comparing the RR of vaccinated patients vs non-vaccinated references. A generalized estimated equation (GEE) was used to handle correlated data for several events in the same individual and included time of follow up as a covariate. We also did a survival analysis (Kaplan-Meier) and Cox regression to investigate time to first event after vaccination.

Results: The point estimate of RRR for pneumonia only was 0.47, 95% CI 0.28-0.77 and for all serious putative pneumococcal infections the RRR was 0.54, 95% CI 0.33-0.89 (Table). Time to first pneumonia or other serious infection after vaccination was significantly shorter among vaccinated patients compared to references (Figure), but after adjusting for number of the same type of infection before vaccination, there was no longer a statistically significant difference after vaccination (p=0.12) and (p=0.09), respectively.

Conclusion: A single dose of heptavalent pneumococcal conjugate vaccine may decrease the risk of putative serious pneumococcal infection up to 10 years after vaccination in adult patients with inflammatory arthritis receiving immunomodulating treatment. However, the vaccine does not seem to prolong the time to first serious infection.

Table. Relative risk (RR) and ratio of relative risk (RRR) of pneumonia and all serious pneumococcal infections among vaccinated and non-vaccinated individuals before and after date of vaccination.

Figure. Cox regression; Time to first event, death or loss of follow-up after date of vaccination for pneumonia only (A), all serious pneumococcal infections (B), adjusted for number of events before date of vaccination.


Disclosure: J. Nagel, None; G. Jönsson, None; J. Nilsson, None; C. Manuswin, None; M. Englund, Pfizer, 5; T. Saxne, None; P. Geborek, None; M. Kapetanovic, None.

To cite this abstract in AMA style:

Nagel J, Jönsson G, Nilsson J, Manuswin C, Englund M, Saxne T, Geborek P, Kapetanovic M. Reduced Risk of Serious Pneumococcal Infection up to 10 Years After Immunization with 7-valent Conjugated Pneumococcal Vaccine in Patients with Inflammatory Arthritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/reduced-risk-of-serious-pneumococcal-infection-up-to-10-years-after-immunization-with-7-valent-conjugated-pneumococcal-vaccine-in-patients-with-inflammatory-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/reduced-risk-of-serious-pneumococcal-infection-up-to-10-years-after-immunization-with-7-valent-conjugated-pneumococcal-vaccine-in-patients-with-inflammatory-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology